Axsome Therapeutics recently reported that the FDA accepted its supplemental application and granted priority review for AXS-05 to treat agitation in Alzheimer’s disease, while also confirming that ...
Shares of GH Research rose on plans to provide an update on the status of its investigational new drug application for GH001, a therapy for treatment-resistant depression. The stock climbed 19% to $15 ...
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...
As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate ...
LAHORE: Artificial intelligence (AI) is enabling researchers to uncover new cancer applications for widely used medicines by ...
US FDA accepts Axsome Therapeutics’ supplemental New Drug Application for AXS-05 to treat Alzheimer’s disease agitation: New York Saturday, January 3, 2026, 12:00 Hrs [IST] Ax ...
FibroBiologics submits IND application with US FDA to initiate clinical trials of CYPS317 in psoriasis patients: Houston Saturday, January 3, 2026, 11:00 Hrs [IST] FibroBiologics ...
The Prescription Drug User Fee Act target guidelines for NDA resubmissions include acknowledgment of acceptance for review ...
Novo Nordisk said on Thursday it had filed a marketing application with the U.S. Food and Drug Administration for CagriSema, its once-weekly next-generation weight-loss drug.
Viatris Inc. (NASDAQ:VTRS) also reported that the Japan Pharmaceuticals and Medical Devices Agency (PMDA) accepted its ...
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback